1. Darpo B, Benson C, Dota C, Ferber G, Garnett C, Green CL, Jarugula V, Johannesen L, Keirns J, Krudys K, Liu J, Ortemann-Renon C, Riley S, Sarapa N, Smith B, Stoltz RR, Zhou M, Stockbridge N (2015) Results from the IQ-CSRC prospective study support replacement of the thorough QT study by QT assessment in the early clinical phase. Clin Pharmcol Ther 97(4):326–335
2. E14 and S7B clinical and nonclinical evaluation of QT/QTc interval prolongation and proarrhythmic potential—questions and answers guidance for industry, August 2022. https://www.fda.gov/media/161198/download. Accessed 16 Feb 2024
3. E14 clinical-evaluation of QT/QTc interval prolongation and proarrhythmic potential-for non-antiarrhythmic-drugs, October 2005. https://www.fda.gov/files/drugs/published/E14-Clinical-Evaluation-of-QT-QTc-Interval-Prolongation-and-Proarrhythmic-Potential-for-Non-Antiarrhythmic-Drugs.pdf. Accessed 16 Feb 2024
4. Li Z, Mirams GR, Yoshinaga T, Ridder BJ, Han X, Chen JE, Stockbridge NL, Wisialowski TA, Damiano B, Severi S, Morissette P, Kowey PR, Holbrook M, Smith G, Rasmusson RL, Liu M, Song Z, Zhilin Q, Leishman DJ, Steidl-Nichols J, Rodriguez B, Bueno-Orovio A, Zhou X, Passini E, Edwards AG, Morotti S, Ni H, Grandi E, Clancy CE, Vandenberg J, Hill A, Nakamura M, Singer T, Polonchuk L, Greiter-Wilke A, Wang K, Nave S, Fullerton A, Sobie EA, Paci M, Tshinanu FM, Strauss DG (2020) General principles for the validation of Proarrhythmia risk prediction models: an extension of the CiPA in silico strategy. Clin Pharmacol Ther 107(1):102–111
5. Liu T, Liu J, Hua Rong L, Li H, Gallacher DJ, Chaudhary K, Wang Y, Yan G-X (2021) Utility of normalized TdP score system in drug Proarrhythmic potential assessment: a blinded in vitro study of CiPA drugs. Clin Pharmcol Ther 109(6):1606–1617